about
Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation TherapyOral High-Dose Multivitamins and Minerals After Myocardial InfarctionLoss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT).Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT)Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial.Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction.Design of the Trial to Assess Chelation Therapy (TACT)Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT).Coronary intervention for persistent occlusion after myocardial infarctionPredictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study.Quality of life after late invasive therapy for occluded arteries.Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).Design and methodology of the Occluded Artery Trial (OAT).Impact of rate-modulated pacing on quality of life and exercise capacity--evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT).Chelation Therapy and Cardiovascular Outcomes—In Reply
P50
Q26747605-506D9DE6-B502-4DE4-B65B-03FC061A13E0Q29012851-EBD1B14B-E4B7-48C2-8031-DB738A1FE65DQ30429019-FE1C2044-9A7F-4EF0-AE4B-66EA2CFE045FQ33792060-F120DF23-80EB-45AA-A843-46096297597AQ33801879-FAB84329-E080-44CF-AEF5-554AA6A1474BQ33952145-80F54948-360F-4CB2-82EE-D62C66BBCF3DQ34098290-D4889045-1F71-4C6F-8D9F-C4D40B40E24EQ35607236-26F1EB1F-4BF9-4AD1-B6EF-3D47BC15FF3EQ35627506-FD488DF5-46B0-421F-BEBA-EBEEB034EEEBQ35840858-9912EB09-5178-462B-97F9-07A6C4F6631CQ36016654-E27F9C2D-6D35-446D-8E53-6F7B458C0031Q37082952-DF82C2CB-818E-4D32-AC52-66A7FA01ACE2Q37298262-8A6C151E-6F9A-4056-A2F7-81F1F58067B1Q49966611-82FBFCA4-A752-4A9A-B3DF-4BE64B5F97A4Q50123794-07885B97-1B80-4338-97A6-023A8A7533C0Q50921010-C96F9AA8-DFEE-4ACF-874B-585251F7127EQ56928523-9FDFA366-C68B-40A6-B957-6A25A093C98A
P50
name
Gervasio A Lamas
@ast
Gervasio A Lamas
@en
Gervasio A Lamas
@nl
type
label
Gervasio A Lamas
@ast
Gervasio A Lamas
@en
Gervasio A Lamas
@nl
prefLabel
Gervasio A Lamas
@ast
Gervasio A Lamas
@en
Gervasio A Lamas
@nl
P214
P214
P31
P734
P7859
lccn-n2015186390